Studying an HIV protein that plays a key role in AIDS progression has helped University of Pittsburgh School of Medicine researchers discover compounds that show promise as novel treatments for the disease.
Study author Thomas E. Smithgall explained that HIV drug discovery efforts have met with little success in finding compounds that interact with an important HIV virulence factor, called Nef, because it lacks biochemical activity that can be directly measured.
AIDS / HIV - Treatment
Encyclopedia section of medindia explains in brief about the treatment for AIDS/HIV
Advertisement
To get around that problem, Smithgall's team developed an assay to measure Nef function indirectly by coupling it to another protein, called Hck, which Nef activates in HIV-infected cells.
Because Hck activity can be easily measured, the researchers were able to use it as a reporter for Nef activity in an automated high-throughput screening process.
![Quiz on HIV / AIDS]( "Quiz on HIV / AIDS")
Statistics tell us that the world HIV+ population has risen drastically from 8 million in 1990 to a whopping 33 million in 2007! Even more alarming is the fact that young people (below the age of 25) account for half of these infections! This is adequate proof for the lack of awareness among the general public even in these modern times. So take our quiz and brush up on the essential facts of HIV/
The researchers screened a library of 10,000 chemical compounds against the coupled proteins to see which ones influenced Nef-induced activation of Hck.
After further testing, they confirmed that three compounds inhibited the activity of the Nef-Hck complex and, more importantly, all of them also interfered with HIV replication.
The researchers found that one compound was so effective that it suppressed HIV replication to undetectable levels in cell culture experiments.
"So we now have a way to rapidly and efficiently screen for inhibitors of Nef signaling through Hck. But the surprise was that some of those inhibitors also showed strong antiviral activity in cell culture models," Smithgall said.
He said that there is evidence that people infected with HIV variants that have mutations in the Nef gene take substantially longer to develop disease symptoms or AIDS. In animal models, disrupting the production of Nef from the virus or its interaction with Hck also delays or prevents disease symptoms.
The study was published in the early, online version of ACS Chemical Biology.
Source: ANI
LIN
Quiz on HIV / AIDS
Statistics tell us that the world HIV+ population has risen drastically from 8 million in 1990 to a whopping 33 million in 2007! Even more alarming is the fact that young people (below the age of 25) account for half of these infections! This is adequate proof for the lack of awareness among the general public even in these modern times. So take our quiz and brush up on the essential facts of HIV/
Advertisement
The researchers screened a library of 10,000 chemical compounds against the coupled proteins to see which ones influenced Nef-induced activation of Hck.
After further testing, they confirmed that three compounds inhibited the activity of the Nef-Hck complex and, more importantly, all of them also interfered with HIV replication.
The researchers found that one compound was so effective that it suppressed HIV replication to undetectable levels in cell culture experiments.
"So we now have a way to rapidly and efficiently screen for inhibitors of Nef signaling through Hck. But the surprise was that some of those inhibitors also showed strong antiviral activity in cell culture models," Smithgall said.
He said that there is evidence that people infected with HIV variants that have mutations in the Nef gene take substantially longer to develop disease symptoms or AIDS. In animal models, disrupting the production of Nef from the virus or its interaction with Hck also delays or prevents disease symptoms.
The study was published in the early, online version of ACS Chemical Biology.
Source: ANI
LIN
HIV Drug Development Should Focus on Immune Cells
HIV drug development should target immune cells called macrophages, a new study has suggested.
Advertisement
Advertisement
|
Advertisement
Recommended Reading
Latest AIDS/HIV News
A new study has found that the co-localization of tuberculosis disease and HIV in lymphatic tissues leads to the emergence of potent HIV antibodies.
Specific antiviral drug that is widely used to treat smallpox patients since last summer's outbreak is found to produce similar outcomes regardless of the patient's HIV status.
In susceptible communities because of poverty, and racism, the effects of inadequate STI and HIV screening may be more profound.
In India, annual HIV infections and AIDS-related deaths continue to drop. Between 2010 and 2021, new HIV infections dropped by 46%.
Globally, all countries have promised to end AIDS by 2030, for which it is essential to safeguard individuals living with HIV to complete HIV care services.